A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy

NCT07688291 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Carcinoma Cell

Interventions

DRUG: PD-1/IL-2α-bias bispecific antibody fusion protein

Sponsor

Beijing GoBroad Hospital